AstraZeneca has been granted a patent for therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The patent includes methods of using a BTK inhibitor to treat CLL and SLL, including specific subtypes of the diseases. Additionally, the patent covers the use of a combination therapy involving a BTK inhibitor and an anti-CD20 antibody. The patent also specifies a specific dosage of 100 mg twice daily for the BTK inhibitor. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AstraZeneca Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Treating cll with a btk inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: AstraZeneca Plc

A recently granted patent (Publication Number: US11771696B2) discloses a method for treating chronic lymphocytic leukemia (CLL) in human subjects. The method involves orally administering a Bruton's tyrosine kinase (BTK) inhibitor at a dose of 100 mg twice daily. The BTK inhibitor used is a compound of Formula (II).

The patent claims also provide additional details regarding the administration of the BTK inhibitor in combination with obinutuzumab, a monoclonal antibody used in CLL treatment. The BTK inhibitor can be administered either before or after obinutuzumab.

Furthermore, the patent claims specify various dosages for obinutuzumab, ranging from 100 mg to 2000 mg. The BTK inhibitor is administered for a period of either 8, 14, 28, or 56 days. The administration of the BTK inhibitor is done at an interval of approximately twelve hours.

It is worth noting that the method described in the patent claims is particularly applicable to human subjects with a 17p13.1 (17p) deletion, a genetic abnormality commonly found in CLL patients.

Overall, this granted patent presents a method for treating CLL using a specific BTK inhibitor in combination with obinutuzumab. The patent claims provide detailed information regarding the dosage, administration schedule, and patient population for this treatment approach. This method has the potential to contribute to the development of more effective treatment options for individuals suffering from CLL, particularly those with a 17p deletion.

To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies